Acute Kidney Injury in Patients Receiving Anti-Tuberculosis Treatment
DOI:
https://doi.org/10.53778/pjkd92302Nøgleord:
acute kidney injury, anti tuberculous treatment, ATT, Rifampicin, Isoniazid, AKIResumé
Although life-saving, anti-tuberculosis therapy (ATT) carries the risk of acute kidney injury (AKI), potentially complicating its management.
Methods: 102 subjects starting on ATT were followed for 2 months. Presence of AKI was documented with monitoring of kidney functions.
Results:
AKI was observed among 14.7% patients, predominantly affecting middle-aged males.
Conclusion:
Early recognition of AKI by monitoring for kidney function is crucial for reducing the risk of long-term sequelae of kidney failure among patients taking ATT.
Downloads
Publiceret
Nummer
Sektion
Licens
Ophavsret (c) 2025 Madiha Mehmood, Dr Muhammad Anees

Dette værk er udgivet under licensen Creative Commons Kreditering–IkkeKommerciel (CC BY-NC).
